Cosmo N.V.

LSE:0RGI Stock Report

Market Cap: CHF 1.1b

Cosmo Valuation

Is 0RGI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 0RGI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 0RGI (CHF66.08) is trading below our estimate of future cash flow value (CHF841.14)

Significantly Below Future Cash Flow Value: 0RGI is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RGI?

Key metric: As 0RGI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0RGI. This is calculated by dividing 0RGI's market cap by their current revenue.
What is 0RGI's PS Ratio?
PS Ratio11.2x
Sales€104.17m
Market Cap€1.17b

Price to Sales Ratio vs Peers

How does 0RGI's PS Ratio compare to its peers?

The above table shows the PS ratio for 0RGI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.7x
HCM HUTCHMED (China)
3.3x13.56%UK£1.4b
AGY Allergy Therapeutics
7.7xn/aUK£443.3m
HIK Hikma Pharmaceuticals
1.3x4.54%UK£3.3b
ANCR Animalcare Group
2.6x5.16%UK£228.9m
0RGI Cosmo
11.2x26.71%CHF 1.1b

Price-To-Sales vs Peers: 0RGI is expensive based on its Price-To-Sales Ratio (11.2x) compared to the peer average (3.7x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 0RGI's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
HIK Hikma Pharmaceuticals
1.3x4.54%US$4.35b
EAH ECO Animal Health Group
0.7x4.71%US$79.07m
No more companies available in this PS range
0RGI 11.2xIndustry Avg. 4.1xNo. of Companies7PS0612182430+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0RGI is expensive based on its Price-To-Sales Ratio (11.2x) compared to the European Pharmaceuticals industry average (4.1x).

Price to Sales Ratio vs Fair Ratio

What is 0RGI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RGI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.2x
Fair PS Ratio7.7x

Price-To-Sales vs Fair Ratio: 0RGI is expensive based on its Price-To-Sales Ratio (11.2x) compared to the estimated Fair Price-To-Sales Ratio (7.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RGI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 66.08
CHF 128.38
+94.27%
15.50%CHF 159.65CHF 100.28n/a5
Jun ’27CHF 75.44
CHF 128.38
+70.19%
15.50%CHF 159.65CHF 100.28n/a5
May ’27CHF 81.43
CHF 129.52
+59.06%
15.37%CHF 160.16CHF 100.60n/a5
Apr ’27CHF 86.20
CHF 123.54
+43.32%
9.99%CHF 139.88CHF 102.30n/a5
Mar ’27CHF 115.40
CHF 116.79
+1.21%
21.40%CHF 150.13CHF 77.93n/a5
Feb ’27CHF 114.40
CHF 104.58
-8.58%
21.12%CHF 130.12CHF 79.23n/a5
Jan ’27CHF 105.20
CHF 98.62
-6.26%
20.42%CHF 130.09CHF 79.94n/a4
Dec ’26CHF 63.09
CHF 98.54
+56.18%
20.66%CHF 130.01CHF 79.57n/a4
Nov ’26CHF 67.50
CHF 87.43
+29.53%
12.02%CHF 102.25CHF 79.01n/a3
Oct ’26CHF 66.31
CHF 87.82
+32.45%
11.84%CHF 102.42CHF 79.01n/a3
Sep ’26CHF 65.07
CHF 87.84
+34.99%
11.82%CHF 102.42CHF 79.01n/a3
Aug ’26CHF 59.30
CHF 98.70
+66.45%
21.55%CHF 132.09CHF 78.68n/a4
Jul ’26CHF 58.90
CHF 101.90
+73.00%
22.17%CHF 132.63CHF 79.00n/a3
Jun ’26CHF 56.90
CHF 101.76
+78.84%
22.25%CHF 132.55CHF 78.73CHF 75.443
May ’26CHF 47.40
CHF 102.21
+115.64%
22.12%CHF 132.83CHF 78.90CHF 81.433
Apr ’26CHF 55.60
CHF 103.52
+86.19%
22.40%CHF 135.18CHF 80.29CHF 86.203
Mar ’26CHF 65.70
CHF 104.03
+58.34%
21.25%CHF 132.62CHF 78.77CHF 115.403
Feb ’26CHF 65.90
CHF 98.41
+49.33%
22.14%CHF 133.03CHF 79.28CHF 114.404
Jan ’26CHF 63.66
CHF 97.48
+53.12%
22.03%CHF 132.13CHF 79.05CHF 105.204
Dec ’25CHF 62.80
CHF 97.48
+55.22%
22.03%CHF 132.13CHF 79.05CHF 63.094
Nov ’25CHF 68.40
CHF 97.34
+42.31%
22.87%CHF 132.93CHF 76.59CHF 67.504
Oct ’25CHF 75.00
CHF 97.13
+29.50%
23.05%CHF 132.99CHF 76.32CHF 66.314
Sep ’25CHF 79.90
CHF 97.38
+21.87%
22.85%CHF 132.96CHF 76.63CHF 65.074
Aug ’25CHF 74.90
CHF 97.38
+30.01%
22.85%CHF 132.96CHF 76.63CHF 59.304
Jul ’25CHF 71.10
CHF 93.19
+31.06%
15.18%CHF 112.82CHF 78.44CHF 58.904
Jun ’25CHF 70.40
CHF 93.09
+32.23%
13.45%CHF 109.09CHF 79.54CHF 56.904
CHF 127.2
Fair Value
48.0% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/29 23:00
End of Day Share Price 2026/06/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cosmo N.V. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Estelle BétriseyBerenberg
Laura HindleyBerenberg
Kerry HolfordBerenberg